Preclinical
Study Data Adds to Similar Efficacy Previously Reported for GeoVax’s Ebola and Lassa Fever Vaccines
CelGro® Human Nerve Regeneration Trial Recently Orthocell announced that the first four patients successfully completed participation in the CelGro® nerve regeneration clinical trial.
In addition to the three preclinical assets from Novartis, Gilead has recently entered into deals to develop therapies for HIV, RA and NASH.
Study reports pre-clinical development of novel treatment and potential for combination use with immunotherapy drugs
Summit Therapeutics plc announced that it highlighted the potential of its preclinical new class antibiotic, SMT-571, to treat all gonorrhoea, including multi-drug and extensively-drug resistant strains, in a poster presentation at the STI & HIV World Congress in Vancouver, Canada.
Pharma and biotech companies from across the globe provide updates on their pipelines and corporate strategy.
Four years ago, Takeda Pharmaceutical Company and The Center for iPS Cell Research and Application (CiRA) at Kyoto University established a 10-year joint research program. Today, the organizations made an announcement.
Multiple sclerosis (MS) is an often-disabling disease of the central nervous system caused by damage to the myelin coating around the nerves.
Imugene Limited, a clinical stage immuno-oncology company, announced new clinical data from the Phase Ib study of its HER-Vaxx cancer vaccine showing cancer fighting antibody and clinical response rates continue to be positive in the patients receiving the optimal biological dose of vaccine.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
PRESS RELEASES